Analysis of novel treatment using Nek2 siRNA for non curative pancreas cancer.

Analysis of novel treatment using Nek2 siRNA for non curative pancreas cancer. - Nek2 siRNA for non curative pancreas cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016330

Enrollment

Registered

2015-01-25

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non curative pancreas cancer.

Interventions

Injection Nek2 SiRNA into the panceatic cancer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.pancreas cancer 2.20y-85y 3.no treatment 4.ECOG PS 0-2 6.Labo data is normal 7.Prognosis is more than 3month. 8.IC

Exclusion criteria

Exclusion criteria: 1.Immunodeficiency 2.Severe Infection 3.Severe complication 4.Pregnant 5.Drug allergy 6.Chronic disease 7.HIV, HBV, HCV 8.others

Design outcomes

Primary

Measure	Time frame
safety: AE within 28days	—

Secondary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactKazuo Hara

Aichi Cancer Center Hospital Gastroenterology

khara@aichi-cc.jp052-762-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026